Strategic Partnerships CPDC collaborates with industry, academia, and government to advance radiopharmaceuticals, presenting multiple entry points for co-development, licensing, or sponsored research deals with pharma, biotech, and healthcare institutions.

Radiopharma Focus Specialization in nuclear medicine and radiopharmaceuticals positions CPDC to partner on imaging agents, therapeutic radiopharmaceuticals, and related diagnostics for Canadian markets, aligning with payer and provider needs.

Not‑for‑Profit Model As a nonprofit with a track record of creating commercial entities, CPDC may be open to grant-funded collaborations, milestone-based funding, and cost-sharing arrangements that reduce upfront risks for potential customers.

Growth Momentum Recent announcement of Lab2Market partnership and program launches indicates active expansion and commercialization activity, signaling available opportunities for technology licensing, joint ventures, or distribution partnerships.

Emerging Canadian Access with revenue in the lower mid-range and a focused Canadian market impact, CPDC offers a gateway for regional suppliers, CROs, and distributors to collaborate on supply, manufacturing partnerships, and clinical development support tailored to Canadian healthcare needs.